CHMP raccomanda l'aggiornamento dell'etichetta del TYSABRI includendo lo status di anticorpo anti virus JC come terzo fattore p

Show Health and Fitness Publications

Tue, April 19, 2011

[ Tue, Apr 19th 2011 ]: Market Wire

MedPro Safety Products and Greiner Bio-One GmbH A .. UETTE® Premium Safety Needle System Tube-Touch®

[ Tue, Apr 19th 2011 ]: Market Wire

Genmab and Seattle Genetics Expand Antibody-Drug Conjugate Collaboration

Mon, April 18, 2011

[ Mon, Apr 18th 2011 ]: Market Wire

CHMP beveelt uitbreiding TYSABRI-bijsluiter aan m .. or anti-JC virus als derde factor om risico PML v

[ Mon, Apr 18th 2011 ]: Market Wire

CHMP recomienda actualizar la etiqueta de TYSABRI .. ti-JCV como tercer factor para estratificar los r

[ Mon, Apr 18th 2011 ]: Market Wire

Community Health Systems to Release 1Q Earnings o .. April 28 to Discuss Financial Results and Address

[ Mon, Apr 18th 2011 ]: Market Wire

Prism Medical Announces Acquisition of Movement 2 Ltd.

[ Mon, Apr 18th 2011 ]: Market Wire

PROTOX ANNOUNCES MOVE TO SAN DIEGO AND SENIOR MANAGEMENT TRANSITION

[ Mon, Apr 18th 2011 ]: Market Wire

BioClinica to Release First Quarter 2011 Financial Results on May 4, 2011

[ Mon, Apr 18th 2011 ]: Market Wire

Community Health Systems Makes All-Cash Offer for Tenet

[ Mon, Apr 18th 2011 ]: Market Wire

Le Comit© des m©dicaments usage humain (CHMP) r .. ©tiquetage de TYSABRI afin d'inclure le statut d

[ Mon, Apr 18th 2011 ]: Market Wire

CHMP empfiehlt Aktualisierung der Produktinformat .. me des JC-Virus-Antikrperstatus als dritten Fakto

[ Mon, Apr 18th 2011 ]: Market Wire

CML HealthCare Inc. Declares April Dividend

[ Mon, Apr 18th 2011 ]: Market Wire

CHMP raccomanda l'aggiornamento dell'etichetta de .. s di anticorpo anti virus JC come terzo fattore p

Sun, April 17, 2011

[ Sun, Apr 17th 2011 ]: Market Wire

Helix BioPharma Corp. to Participate in Upcoming .. n New York Focused on Women's Health and Wellness

[ Sun, Apr 17th 2011 ]: Market Wire

CHMP Recommends Updating TYSABRI Labeling with an .. as a Third Factor to Further Stratify Risk of PML

[ Sun, Apr 17th 2011 ]: Market Wire

D. Medical Enters US$10 Million Standby Equity Agreement

Fri, April 15, 2011

[ Fri, Apr 15th 2011 ]: Market Wire

Health Management Associates, Inc. Announces Firs .. Quarter 2011 Earnings Conference Call and Webcast

[ Fri, Apr 15th 2011 ]: Market Wire

The Law Offices of Vincent Wong Announce an Inves .. es of Fiduciary Duty by the Board of American Med

[ Fri, Apr 15th 2011 ]: Market Wire

Amedisys to Present at the 15th Annual Burkenroad Reports Investment Conference

[ Fri, Apr 15th 2011 ]: Market Wire

Merck Commences Tender Offer for all Outstanding Shares of Inspire Pharmaceuticals, Inc.

[ Fri, Apr 15th 2011 ]: Market Wire

Vertex Announces the Date of its First Quarter 2011 Financial Results Conference Call and Webcast

[ Fri, Apr 15th 2011 ]: Market Wire

Preliminary Injunction Ordered in POZEN Treximet Patent Litigation

[ Fri, Apr 15th 2011 ]: Market Wire

ImmunoCellular Therapeuticsa? Cancer Vaccine: Saf .. Results for Glioblastoma Trial Presented at Ameri

[ Fri, Apr 15th 2011 ]: Market Wire

Bydureona" Recommended for Approval in Europe

[ Fri, Apr 15th 2011 ]: Market Wire

Merck Reaffirms 2011 Non-GAAP EPS Target

[ Fri, Apr 15th 2011 ]: Market Wire

Repligen Announces Conference Call to Discuss Pre .. ancial Results and Fiscal Year 2012 Corporate Goa

[ Fri, Apr 15th 2011 ]: Market Wire

Merck and Johnson & Johnson Reach Agreement on Distribution Rights for REMICADE® and SIMPONI®

Thu, April 14, 2011

[ Thu, Apr 14th 2011 ]: Market Wire

Osiris Therapeutics Wins Top Scoring Abstract at the 24th Annual Symposium on Advanced Wound Care

[ Thu, Apr 14th 2011 ]: Market Wire

New Study Demonstrated Significant Reduction in A .. lting of Disability Progression in MS Patients Sw

[ Thu, Apr 14th 2011 ]: Market Wire

Tornier Announces Launch of BioFiber® Surgical M .. Tendon Repair at Arthroscopic Surgery Conference

[ Thu, Apr 14th 2011 ]: Market Wire

Geron to Webcast Analyst and Investor Meeting on .. ompanya?s Cell Therapy Programs on April 19, 2011

[ Thu, Apr 14th 2011 ]: Market Wire

InSite Vision Updates Special Protocol Assessment .. or Phase 3 Trial of AzaSite Plusa" and DexaSitea"

[ Thu, Apr 14th 2011 ]: Market Wire

Catasys Program to Benefit from Health Care Reform

[ Thu, Apr 14th 2011 ]: Market Wire

MedMira';s Multiplo Rapid Test to Be Used by Canadian Forces Health Services Group

[ Thu, Apr 14th 2011 ]: Market Wire

St. Jude Medical Announces Approval of ShockGuard .. onTxa" Programming for Unify and Fortify Implanta

[ Thu, Apr 14th 2011 ]: Market Wire

RXi Pharmaceuticals Completes Apthera Acquisition

[ Thu, Apr 14th 2011 ]: Market Wire

Human Genome Sciences Updates Investors on Progress of BENLYSTA® Launch and Future Priorities

[ Thu, Apr 14th 2011 ]: Market Wire

Medisafe 1 Technologies Closes $5 Million Equity Funding Agreement

Wed, April 13, 2011

[ Wed, Apr 13th 2011 ]: Market Wire

NPS Pharmaceuticals Prices Upsized Public Offering of Common Stock

[ Wed, Apr 13th 2011 ]: Market Wire

Hagens Berman LLP Continues Investigation of Community Health and Tenet

[ Wed, Apr 13th 2011 ]: Market Wire

CardioComm Solutions, Inc. Issues Common Shares for Services

[ Wed, Apr 13th 2011 ]: Market Wire

La Jolla Pharmaceutical Company Announces Reverse Stock Split

[ Wed, Apr 13th 2011 ]: Market Wire

Forest Laboratories Chairman and CEO to Challenge .. teda Potential Action to Exclude Him from Federal

[ Wed, Apr 13th 2011 ]: Market Wire

Shoal Point Energy Ltd. Finalizes Farmin Agreemen .. tarmigan Energy Inc. on Exploration Licence #1120

[ Wed, Apr 13th 2011 ]: Market Wire

Baxter Supports New Advocacy in Action Initiative .. Bleeding Disorders to Achieve and Maintain Acces

[ Wed, Apr 13th 2011 ]: Market Wire

Forest Laboratories Completes Acquisition of Clinical Data, Inc.

[ Wed, Apr 13th 2011 ]: Market Wire

The Medicines Company to Announce First Quarter 2 .. 11 Financial Results on Wednesday, April 27, 2011

[ Wed, Apr 13th 2011 ]: Market Wire

Gilead Sciences to Release First Quarter 2011 Financial Results on Wednesday, April 20, 2011

CHMP raccomanda l'aggiornamento dell'etichetta del TYSABRI includendo lo status di anticorpo anti virus JC come terzo fattore p

//health-fitness.news-articles.net/content/2011/ .. nticorpo-anti-virus-jc-come-terzo-fattore-p.html

Published in Health and Fitness on Monday, April 18th 2011 at 3:00 GMT by Market Wire
^{🞛 This publication is a summary or evaluation of another publication}

WESTON, Massachusetts & DUBLINO--([ BUSINESS WIRE ])--[ Biogen Idec ] (NASDAQ: BIIB) ed [ Elan Corporation ], plc (NYSE: ELN) hanno annunciato oggi che il Comitato per i medicinali per uso umano (CHMP) ha espresso un parere positivo sull'inclusione di un ulteriore fattore di rischio, status di anticorpo JCV (anti virus JC), nell'etichetta prodotto del [ TYSABRI ]^� (natalizumab) nell'Unione Europea (UE). Il CHMP ha espresso un parere positivo sul rinnovo quinquennale dell'autorizzazione alla commercializzazione del TYSABRI.

Il testo originale del presente annuncio, redatto nella lingua di partenza, la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodit del lettore e devono rinviare al testo in lingua originale, che l'unico giuridicamente valido.